ATE331518T1 - Methode zur behandlung von fettsucht anhand eines neurotensinreceptor-liganden - Google Patents

Methode zur behandlung von fettsucht anhand eines neurotensinreceptor-liganden

Info

Publication number
ATE331518T1
ATE331518T1 AT01303855T AT01303855T ATE331518T1 AT E331518 T1 ATE331518 T1 AT E331518T1 AT 01303855 T AT01303855 T AT 01303855T AT 01303855 T AT01303855 T AT 01303855T AT E331518 T1 ATE331518 T1 AT E331518T1
Authority
AT
Austria
Prior art keywords
receptor ligand
neurotensin receptor
treating obesity
relates
present
Prior art date
Application number
AT01303855T
Other languages
English (en)
Inventor
John Richard Neville Hadcock
Point Road Eastern
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22739686&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE331518(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of ATE331518T1 publication Critical patent/ATE331518T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
AT01303855T 2000-04-27 2001-04-27 Methode zur behandlung von fettsucht anhand eines neurotensinreceptor-liganden ATE331518T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19995100P 2000-04-27 2000-04-27

Publications (1)

Publication Number Publication Date
ATE331518T1 true ATE331518T1 (de) 2006-07-15

Family

ID=22739686

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01303855T ATE331518T1 (de) 2000-04-27 2001-04-27 Methode zur behandlung von fettsucht anhand eines neurotensinreceptor-liganden

Country Status (13)

Country Link
US (1) US6699832B2 (de)
EP (1) EP1157695B1 (de)
JP (1) JP2002275092A (de)
KR (1) KR20010098829A (de)
AT (1) ATE331518T1 (de)
AU (1) AU3888801A (de)
CA (1) CA2345180A1 (de)
DE (1) DE60121096T2 (de)
ES (1) ES2264679T3 (de)
HU (1) HUP0101666A3 (de)
IL (1) IL142707A0 (de)
NZ (1) NZ511354A (de)
ZA (1) ZA200103365B (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US6693130B2 (en) * 1999-02-18 2004-02-17 Regents Of The University Of California Inhibitors of epoxide hydrolases for the treatment of hypertension
US8815951B2 (en) * 1996-08-13 2014-08-26 The Regents Of The University Of California Inhibitors of epoxide hydrolases for the treatment of inflammation
EP2213743A1 (de) 2000-04-12 2010-08-04 Human Genome Sciences, Inc. Albuminfusionsproteine
GB0107383D0 (en) * 2001-03-23 2001-05-16 Univ Edinburgh Lipid profile modulation
CN1820756A (zh) * 2001-03-23 2006-08-23 科塞普特治疗公司 使用糖皮质激素受体特效拮抗剂治疗压力症的方法
GB0121709D0 (en) * 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
CN100350968C (zh) * 2001-09-24 2007-11-28 皇家创新有限公司 饮食行为的改进
AU2002364586A1 (en) 2001-12-21 2003-07-30 Delta Biotechnology Limited Albumin fusion proteins
WO2005003296A2 (en) 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Albumin fusion proteins
US8058233B2 (en) * 2002-01-10 2011-11-15 Oregon Health And Science University Modification of feeding behavior using PYY and GLP-1
CA2480858A1 (en) * 2002-04-10 2003-10-23 Eli Lilly And Company Treatment of gastroparesis
WO2003093829A1 (en) * 2002-05-02 2003-11-13 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with neurotensin receptor 2 (nt2)
AU2003229736A1 (en) * 2002-05-02 2003-11-17 Bayer Aktiengesellschaft Diagnostics and therapeutics for diseases associated with neurotensin receptor 1 (nt1)
US20040077650A1 (en) * 2002-10-18 2004-04-22 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
EP1891966B1 (de) 2002-12-20 2012-02-15 H. Lundbeck A/S Modulation der Neurotrophinaktivität;Screeningsverfahren
GB0300571D0 (en) * 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
CN1964630A (zh) * 2003-02-13 2007-05-16 耶希瓦大学艾伯塔·爱恩斯坦医学院 通过控制下丘脑的长链脂肪酰基－辅酶A(LC－CoA)的水平来调控食物摄取和葡萄糖产生
US20050222040A1 (en) * 2004-04-05 2005-10-06 Blm Group, Inc. Vertebrate peptide modulators of lipid metabolism
WO2006041922A2 (en) * 2004-10-08 2006-04-20 Dara Biosciences, Inc. Agents and methods for administration to the central nervous system
US20090012067A1 (en) * 2005-02-14 2009-01-08 Luciano Rossetti Modulation of Hypothalamic Atp-Sensitive Potassium Channels
GB0511986D0 (en) * 2005-06-13 2005-07-20 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
TWI428346B (zh) * 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
RS60019B1 (sr) 2006-12-21 2020-04-30 H Lundbeck As Modulacija aktivnosti proneurotrofina
WO2009033808A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
US20100173829A1 (en) * 2008-11-07 2010-07-08 Aston University Glycoproteins Having Lipid Mobilizing Properties and Therapeutic Uses Thereof
CA2745524C (en) 2008-12-05 2020-06-09 Angiochem Inc. Conjugates of neurotensin or neurotensin analogs and uses thereof
WO2011156557A2 (en) * 2010-06-11 2011-12-15 Thomas James B Compounds active at the neurotensin receptor
JP2013530993A (ja) 2010-07-02 2013-08-01 アンジオケム インコーポレーテッド 治療用コンジュゲートのための短く且つｄ−アミノ酸を含有するポリペプチドおよびその使用
US8476221B2 (en) * 2011-03-18 2013-07-02 Halimed Pharmaceuticals, Inc. Methods and compositions for the treatment of metabolic disorders
CN103308670B (zh) * 2012-03-08 2017-06-09 思芬构技术有限公司 用于预测对象患糖尿病和/或代谢综合征的风险的方法
US20150050371A1 (en) 2012-03-09 2015-02-19 Biotropics Malaysia Berhad Extract Formulations of Rhodamnia Cinerea And Uses Thereof
WO2014071128A1 (en) 2012-11-02 2014-05-08 The Brigham And Women's Hospital, Inc. Macrophage-derived matrix vesicles: an alternative mechanism for microcalcification in atherosclerotic plaques
JP6239635B2 (ja) 2012-11-02 2017-11-29 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． 血管石灰化の誘導因子であるソルチリン１
SI3380495T1 (sl) 2015-11-24 2022-01-31 Transfert Plus, S.E.C. Peptidne spojine in peptidni konjugati za zdravljenje raka z receptorsko posredovano kemoterapijo
US10473670B2 (en) * 2016-02-25 2019-11-12 University Of Kentucky Research Foundation Method of predicting obesity comprising measuring neurotensin

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4110321A (en) 1976-07-12 1978-08-29 Folkers Karl Synthetic tridecapeptide [Gln4 ]-neurotensin having hormonal activity
US5217953A (en) 1990-11-30 1993-06-08 The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services Vasoactive intestinal peptide antagonist
US5250558A (en) 1992-01-28 1993-10-05 Merck & Co., Inc. Substituted triazolinones, triazolinethiones, and triazolinimines as neurotensin antagonists used to treat psychosis
US5204354A (en) 1992-02-14 1993-04-20 Merck & Co., Inc. Substituted quinazolinones as neurotensin antagonists useful in the treatment of CNS disorders
US5407916A (en) 1993-02-16 1995-04-18 Warner-Lambert Company Neurotensin mimetics as central nervous system agents
FR2711140B1 (fr) * 1993-10-12 1996-01-05 Sanofi Sa 1-Naphtylpyrazole-3-carboxamides substitués actifs sur la neurotensine, leur préparation, les compositions pharmaceutiques en contenant.
FR2760750B1 (fr) 1997-03-17 1999-05-28 Sanofi Sa Recepteur humain a la neurotensine de type 2(hnt-r2)
US6008050A (en) 1997-04-02 1999-12-28 Smithkline Beecham Corporation Human neurotensin receptor type 2 and splice variants thereof
US6274720B1 (en) * 1997-12-31 2001-08-14 Incyte Genomics, Inc. Human preproneurotensin/neuromedin N
US6420137B1 (en) 1998-11-25 2002-07-16 American Home Products Corporation Nucleic acid encoding human neurotensin subtype 2 receptor

Also Published As

Publication number Publication date
JP2002275092A (ja) 2002-09-25
IL142707A0 (en) 2002-03-10
KR20010098829A (ko) 2001-11-08
DE60121096D1 (de) 2006-08-10
HU0101666D0 (en) 2001-06-28
HUP0101666A3 (en) 2003-03-28
CA2345180A1 (en) 2001-10-27
DE60121096T2 (de) 2006-12-07
ES2264679T3 (es) 2007-01-16
US20010046956A1 (en) 2001-11-29
HUP0101666A2 (hu) 2002-02-28
EP1157695B1 (de) 2006-06-28
NZ511354A (en) 2003-03-28
US6699832B2 (en) 2004-03-02
EP1157695A1 (de) 2001-11-28
AU3888801A (en) 2001-11-01
ZA200103365B (en) 2002-10-25

Similar Documents

Publication Publication Date Title
ATE331518T1 (de) Methode zur behandlung von fettsucht anhand eines neurotensinreceptor-liganden
TNSN06010A1 (en) Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
ATE480255T1 (de) Zusammensetzungen und verfahren zur kontrolle, prävention und behandlung von essstörungen
DE60223058D1 (de) Zusammensetzungen und verfahren zur behandlung von diabetes
ATE495715T1 (de) Filtermembran mit vergrösserter oberfläche
BRPI0508390A (pt) métodos para tratamento de dor de cáncer de osso através da administração de um antagonista de fator de crescimento de nervo
EA200601555A1 (ru) Замещенные индазол-о-глюкозиды
ATE521357T1 (de) Verfahren zur behandlung von hepatitis
DE602004021847D1 (de) Verfahren zur prävention und behandlung von diabetes mit neurturin
EP1706128A4 (de) Pharmazeutische zusammensetzungen und verfahren für die insulinbehandlung
ATE321880T1 (de) Nachweisverfahren für verbindungen, welche die somatostatin- und insulinproduktion stimulieren
ATE425151T1 (de) Verfahren zur racematspaltung von 2,4-diamino-3,6-dihydro-1,3,5-triazinen, die sich zur behandlung von mit dem insulinresistenzsyndrom assoziierten erkrankungen eignen
WO2004009064A8 (de) Verwendung von neurotoxischen substanzen für die herstellung eines mittels zur behandlung von gelenkschmerzen und verfahren zur applikation dieses mittels
AU2003215190A8 (en) Methods and compositions for treating aids and hiv-related disorders using 1414, 1481, 1553, 34021, 1720, 1683, 1552, 1682, 1675, 12825, 9952, 5816, 10002, 1611, 1371, 14324, 126, 270, 312, 167, 326, 18926, 6747, 1793, 1784, or 2045 molecules.
ATE413867T1 (de) Methode zur behandlung von bewegungsstörungen mit barbitursäure derivaten.
CY1110156T1 (el) Υποκατεστημενες ενωσεις 4,5,6,7-τετραϋδρο-βενζοθειαζολ-2-υλαμινης
ATE453386T1 (de) Polyamin-verbindungen zur behandlung von chemokin-rezeptor-vermittelten krankheiten
DE60239864D1 (de) Kondensierte thiophene verbindungen und deren verwendung zur behandlung von chronischen schmerzen
MXPA05009428A (es) Composiciones y metodos para prevenir y tratar enfermedades relacionadas con endotoxinas.
DK1208213T3 (da) Fremgangsmåde til fremstilling af proteiner i værtsceller under anvendelse af chaperoniner
ATE375798T1 (de) Verwendung von e5564 zur behandlung von sepsis durch intravenöse infusion
EP1370697A4 (de) Peroxiredoxin-arzneistoffe zur behandlung einer hiv-1-infektion und verfahren zu deren verwendung
DE60327655D1 (de) Verfahren zur behandlung von durch taxol induzierter sensorischer neuropathie
BRPI0414718A (pt) aprocesso que permite evitar ou reduzir a obstrução de mebranas de filtração
EA200601402A1 (ru) L-(+)-тартрат l-(-)- мопролола

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties